Cryoprecipitate and treatment of factor VIII deficiency
In the surgeon's arsenal, cryoprecipitate plays an important role in treating specific coagulopathies. This agent is prepared from blood plasma and is traditionally produced in liquid form (15 ml vials). Its main task is the cessation and prevention of bleeding in patients with congenital or acquired coagulation disorders.
The complex composition of cryoprecipitate includes vital hemostatic components:
- Antihemophilic globulin (coagulation factor VIII).
- Fibrin-stabilizing factor (coagulation factor XIII).
- Fibrinogen.
The primary indications for prescribing cryoprecipitate are coagulation disorders caused by factor VIII deficiency. This primarily concerns pathologies such as hemophilia A and von Willebrand disease. Administration of the drug compensates for the deficiency of antihemophilic globulin and prevents life-threatening bleeding during trauma or surgical interventions.
Prothrombin complex
Like other agents in this group, the prothrombin complex is prepared from blood plasma. Its distinguishing feature is a high, concentrated content of a series of clotting factors. The preparation includes factors II, VII, IX, and X.
The use of the prothrombin complex aims to stop and prevent bleeding in entirely different conditions compared to cryoprecipitate. Strict indications for its prescription include:
- Hemophilia B.
- Hypoprothrombinemia.
- Hypoproconvertinemia.
Due to the high concentration of these factors, the drug rapidly restores the blood's coagulative potential in patients with these specific deficiencies.
Fibrinogen
The drug fibrinogen is also obtained from blood plasma. It is a transfusion medium containing the protein of the same name (fibrinogen) in a highly concentrated form. The drug is actively used for both therapeutic and prophylactic purposes in various fields of medicine, from general surgery to obstetrics.
Indications for the use of fibrinogen are quite broad:
- Congenital and acquired hypofibrinogenemia and afibrinogenemia.
- Development of profuse bleeding of various etiologies.
- Prevention of hemorrhagic complications in the early postoperative period.
- Management of bleeding during and after childbirth in obstetric practice.
Timely administration of concentrated fibrinogen allows for the rapid formation of a dense fibrin clot and halts massive blood loss.
Thrombin: agent for local hemostasis
Unlike the agents described above, thrombin has a fundamentally different route of administration. It is prepared from blood plasma and produced as a dry powder in vials. Its multicomponent composition includes thrombin itself, as well as thromboplastin and calcium chloride.
Crucial rule: thrombin is used topically only! Its systemic (intravenous) administration is strictly prohibited.
In surgical practice, local application of thrombin is indicated in the following situations:
- Cessation of persistent capillary bleeding in the wound.
- Parenchymal bleeding occurring in the presence of extensive wounds or during extensive surgeries on parenchymal organs (liver, spleen, kidneys).
Applying the drug directly to the bleeding surface ensures instant activation of local hemostasis and the formation of a reliable thrombus.
Briefly: answers to topical questions
What hemostatic components are part of cryoprecipitate?
Cryoprecipitate contains the following components of the clotting system: antihemophilic globulin (factor VIII), fibrin-stabilizing factor (factor XIII), fibrinogen, von Willebrand factor, and fibronectin.
Which clotting factors does the prothrombin complex contain?
The prothrombin complex concentrate contains a high concentration of vitamin K-dependent blood clotting factors: factor II, factor VII, factor IX, and factor X, as well as proteins C and S.
How to properly reconstitute dry thrombin powder before applying it to a bleeding surface?
Before topical application, dry thrombin powder is dissolved in an isotonic sodium chloride solution. Sterile wipes or a hemostatic sponge are saturated with the resulting solution and then applied to the wound.
To avoid confusing indications: Cryoprecipitate (contains factor VIII) treats hemophilia A, while Prothrombin complex treats hemophilia B.
Class and exam questions
What are all the listed hemostatic drugs produced from?
Cryoprecipitate, prothrombin complex, fibrinogen, and thrombin are prepared exclusively from blood plasma.
What is the main difference in the application of thrombin compared to other drugs?
Thrombin is used strictly topically (as a powder) to stop capillary and parenchymal bleeding. Its intravenous administration is unacceptable.
For the treatment of which pathology is cryoprecipitate indicated?
Cryoprecipitate is indicated for coagulation disorders caused by factor VIII deficiency, particularly in hemophilia A and von Willebrand disease.
What else to study on this topic
- Mechanism of action of factors II, VII, and X in the coagulation cascade
- Differences between hemophilia A and hemophilia B
- Etiology and pathogenesis of von Willebrand disease
- Causes of congenital and acquired afibrinogenemia
- Features of surgical hemostasis during operations on parenchymal organs
Master the entire topic in the "General Surgery" course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Hemostatic blood products" and 3,335 more pages of the subject
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 70 video lessons on the subject
Other topics in the section "CHAPTER 6. BLOOD TRANSFUSION"
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.